Inventiva S.A. (IVA)
IVA Stock Price Chart
Explore Inventiva S.A. interactive price chart. Choose custom timeframes to analyze IVA price movements and trends.
IVA Company Profile
Discover essential business fundamentals and corporate details for Inventiva S.A. (IVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jul 2020
Employees
114.00
Website
https://www.inventivapharma.comCEO
Andrew Obenshain
Description
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
IVA Financial Timeline
Browse a chronological timeline of Inventiva S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Sept 2026
EPS estimate is -$0.42, while revenue estimate is $762.20k.
Earnings released on 30 Mar 2026
EPS came in at -$1.07 falling short of the estimated -$0.23 by -365.22%, while revenue for the quarter reached $2.30m , missing expectations by -55.34%.
Earnings released on 25 Sept 2025
EPS came in at -$1.89 falling short of the estimated -$0.41 by -361.73%, while revenue for the quarter reached $5.22m , missing expectations by -39.84%.
Earnings released on 23 May 2025
EPS came in at -$2.69 falling short of the estimated -$0.47 by -472.95%, while revenue for the quarter reached $6.69m , beating expectations by +4.61%.
Earnings released on 25 Sept 2024
EPS came in at -$1.01 falling short of the estimated -$0.56 by -81.10%, while revenue for the quarter reached $2.94m .
Earnings released on 27 Mar 2024
EPS came in at -$1.25 falling short of the estimated -$0.40 by -211.66%, while revenue for the quarter reached $18.19m , beating expectations by +18.93%.
Earnings released on 28 Sept 2023
EPS came in at -$1.43 falling short of the estimated -$1.27 by -13.09%, while revenue for the quarter reached $7.22m , beating expectations by +419.32%.
Earnings released on 29 Mar 2023
EPS came in at -$0.64 falling short of the estimated -$0.57 by -11.90%, while revenue for the quarter reached $16.61m , beating expectations by +5.80%.
Earnings released on 19 Sept 2022
EPS came in at -$0.75 surpassing the estimated -$0.90 by +16.59%, while revenue for the quarter reached $70.08k , missing expectations by -94.44%.
Earnings released on 3 Mar 2022
EPS came in at -$0.76 surpassing the estimated -$0.90 by +15.33%, while revenue for the quarter reached $4.60m , beating expectations by +31.17%.
Earnings released on 20 Sept 2021
EPS came in at -$0.46 surpassing the estimated -$0.91 by +48.96%, while revenue for the quarter reached $77.12k , missing expectations by -35.11%.
IVA Stock Performance
Access detailed IVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
